1. In Vivo

US Generics Players Enjoy Calmer Waters

After Some Tumultuous Years, Pressures In The US Market Have Eased In Recent Quarters

 
• By Dave Wallace

After years of heavy price and cost pressures that have taken a toll on firms operating in the US generics market, more recent quarters appear to have reflected a calmer and more predictable landscape.     

Pricing is cyclical for generics companies
Generics companies have experienced cyclical pricing trends in the US • Source: Shutterstock

Historically, the US generics market tends to yo-yo between periods of intense pricing and cost pressure on suppliers that then give way to calmer periods, which allow the industry to regroup amid a slightly more favorable operating environment. And based on the latest indications from leading players, it seems that the market has lately swung back towards the latter.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Intelligence

More from In Vivo

Podcast: Ochre Bio’s Approach To Precision Medicine In Liver Treatment

 
• By David Wild

Ochre Bio co-founder and CSO Quin Wills spoke with In Vivo about the UK-based company's novel approach to finding RNA therapies for chronic liver disease.

Richard DiMarchi On The GLP-1 Revolution: An Overnight Success After 40 Years

 
• By Andrew Warmington

As GLP-1 agonists surge to blockbuster status transforming diabetes and obesity treatment, Richard DiMarchi, the pioneering scientist behind their development, recounts the inside story of the drug class in a fireside chat.

Rising Leaders 2025: João Ribas On Building At The Intersection Of Science And Business

 
• By Jo Shorthouse

João Ribas combines scientific expertise with venture capital at Novo Holdings, applying his dual background to develop biotech investments that connect academic research with commercial opportunity.